Advertisement

Cancer Therapy pp 284-291 | Cite as

New Approaches in the Hormonal Therapy of Breast Cancer

  • K. Höffken
Conference paper

Abstract

Hormonal therapy plays a central role in the overall treatment strategy of sex-specific cancer. Long before the detection of hormones and hormone receptors, ablation of sex hormone glands became part of the treatment of breast and prostate cancer because, in spite of malignancy, the cell growth retained hormone dependence. Moreover, the demonstration of estrogen and/or progesterone receptors as a predictor for the effectiveness of hormonal manipulations in two-thirds to three- fourths of all breast cancers warranted further research in this field.

Keywords

Breast Cancer Metastatic Breast Cancer Advanced Breast Cancer Premenopausal Patient LHRH Agonist 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Beatson GT (1896) On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet 2:104–107, 162–165Google Scholar
  2. 2.
    Bonneterre J, Coppens H, Mauriac L, Metz M, Rouesse J, Armand JP, Fargeot P, Mathieu M, Tubiana M, Cappelaere P (1985) Aminoglutethimide in advanced breast cancer: Clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day. Europ J Cancer Clin Oncol 21: 1153–1158PubMedCrossRefGoogle Scholar
  3. 3.
    Brodie AMH, Garrett WM, Tsai-Morris CH, Wink LC (1984) Aromatase inhibition: a new perspective in the treatment of breast cancer. In: Nagel G A, Santen RJ (eds) Aminoglutethimide as an aromatase inhibitor in the treatment of cancer. 13th International Congress of Chemotherapy, Vienna, Hans Huber, Berne, pp 11–23Google Scholar
  4. 4.
    Camacho AM, Brough AJ, Cash R, Wilroy RS (1966) Adrenal toxicity associated with the administration of an anticonvulsant drug. J Pediatr 68: 852–853Google Scholar
  5. 5.
    Cash R, Brough AJ, Cohen MNP, Satoh PS (1967) Aminoglutethimide as an inhibitor of adrenal steroidgenesis: mechanism of action and therapeutic trial. J Clin Endocrinol Metab 27: 1239–1248PubMedCrossRefGoogle Scholar
  6. 6.
    Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M, Brodie AMH (1987) 4-Hydroxyandrostenedione treatment for postmenopausal patients with advanced breast cancer. Tumor Diag Ther 8: 271–273Google Scholar
  7. 7.
    Foekens JA, Henkelmann MS, Fukkink JF, Blankenstein MA, Klijn JGM (1986) Direct effects of LHRH analogs on tumor cells. Eur J Cancer (abstr III-s) 22: 725Google Scholar
  8. 8.
    Foekens JA, Henkelmann MS, Bolt-de Vries J, Portengen H, Fukkink JF, Blankenstein MA, van Steenbrugge GJ, Mulder E, Klijn JGM (1987) Direct effects of LHRH analogs on breast and prostatic tumor cells. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, pp 369-380 (Monograph series of the european organization for research on treatment of cancer [EORTC], vol 18 )Google Scholar
  9. 9.
    Gale KE (1982) Treatment of advanced breast cancer with aminoglutethimide. A 14-year experience. Cancer Res [suppl] 42: 3389s–3396sGoogle Scholar
  10. 10.
    Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB (1973) Preliminary trial of aminoglutethimide in breast cancer. Cancer 32: 31–37PubMedCrossRefGoogle Scholar
  11. 11.
    Harris AL, Dowsett M, Smith IE, Jeffcoate SL (1983) Endocrine effects of low-dose aminoglutethimide alone in advanced postmenopausal breast cancer. Br J Cancer 47: 621–627PubMedCrossRefGoogle Scholar
  12. 12.
    Harris AL, Powles TJ, Smith IE, Coombes RC, Ford HT, Gazet JC, Harmer CL, Morgan M, White M, Parsons CA, McKinna JA (1983) Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. Eur J Cancer Clin Oncol 29: 11–17CrossRefGoogle Scholar
  13. 13.
    Harvey HA, Lipton A, Santen RJ, Escher GC, Hardy MA, Glode LM, Sealoff A, Landau RL, Schneir H, Max DT (1981) Phase II study of a gonadotropin-releasing hormone analogue (Leuprolide) in postmenopausal advanced breast cancer patients. Proc Am Ass Cancer Res Am Soc Clin Oncol (Abstract C-436) 22: 444Google Scholar
  14. 14.
    Harvey HA, Lipton A, Max DT, Pearlman OHG, Diaz-Perches R, de la Garza J (1984) Effective medical castration produced by the GnRH analog Leuprolide in metastatic breast cancer. Proc Am Soc Clin Oncol (abstr C-435) 3: 111Google Scholar
  15. 15.
    Henderson IC, Cannelos GP (1980) Cancer of the breast. The past decade: Part 1. New Engl J Med 302: 17–30PubMedCrossRefGoogle Scholar
  16. 16.
    Höffken K, Kempf H, Miller AA, Miller B, Schmidt CG, Faber P, Kley HK (1986) Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer. Cancer Treat Rep 70: 1153–1157PubMedGoogle Scholar
  17. 17.
    Höffken K, Miller AA, Miller B, Becher R, Aulbert E, Hoffmann B, Anders CU, Callies R, Schmidt CG (1986) Niedrigdosierte Aminoglutethimid-Therapie ohne Cortisolsubstitution beim metastasierenden Mammakarzinom in der Postmenopause. Med Klin 81: 638–642Google Scholar
  18. 18.
    Höffken K, Jonat W, Possinger K, Kölbel M, Kunz T, Becher R, Callies R (1988) Aromatase inhibition with 4-hydroxyandrostenedione (4-OHA) in treatment of postmenopausal advanced breast cancer (BC). Verh Dtsch Krebsgesellschaft (to be published)Google Scholar
  19. 19.
    Höffken K, Oesterdickhoff C, Becher R, Callies R, Kurschel E, Anders CU, Scheulen ME, Schmidt CG (1989) LH-RH agonist treatment with Buserilin in premenopausal patients with advanced breast cancer: a phase II study. Cancer Ther Contr 1: (in press)Google Scholar
  20. 20.
    Hoogstraten B, Gad-el-Mawla N, Maloney TR, Fletcher WS, Vaughn CB, Tranum BL, Athens JW, Costanzi JJ, Foulkes M (1984) Combined modality therapy for first recurrence of breast cancer. A Southwest Oncology Group Study. Cancer 54: 2248–2256Google Scholar
  21. 21.
    Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL, Chang MN, Bisel HF, Windschitl HE, Twito DI, Pfeifle DM (1986) Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 4: 178–185PubMedGoogle Scholar
  22. 22.
    Klijn JGM, de Jong FH (1982) Treatment with a luteinising hormone-releasing hormone ana-logue (Buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1: 1213–1216Google Scholar
  23. 23.
    Klijn JGM, de Jong FH, Lamberts SWJ, Blankenstein MA (1985) LHRH-agonist treatment in clinical and experimental human breast cancer. J Steroid Biochem 23: 867–873Google Scholar
  24. 24.
    Klijn JGM, Paridaens R, Foekens JA (eds) (1987) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, ( Monograph series of the european organization for research on treatment of cancer [EORTC]. vol 18 )Google Scholar
  25. 25.
    Klijn JGM, de Jong FH (1987) Long-term LHRH-agonist (Buserelin) treatment in metastatic premenopausal breast cancer. In: Klijn JGM, Paridaens R, Foekens JA (eds) Hormonal manipulation of cancer: peptides, growth factors, and new (anti) steroidal agents. Raven, New York, pp 343–352 (Monograph series of the european organization for research on treatment of cancer [EORTC], vol 18 )Google Scholar
  26. 26.
    Miller AA, Miller BE, Höffken K, Schmidt CG (1987) Clinical pharmacology of aminoglutethimide in patients with metastatic breast cancer. Cancer Chemother Pharmacol 20: 337–341PubMedCrossRefGoogle Scholar
  27. 27.
    Miller AA, Miller BE, Höffken K, Schmidt CG (1987) Conventional-dose aminoglutethimide without hydrocortisone replacement in patients with postmenopausal breast cancer: serum Cortisol levels and response to ACTH stimulation. J Exp Clin Cancer Res 16: 135–138Google Scholar
  28. 28.
    Murray R, Pitt P (1985) Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer. Eur J Cancer Clin Oncol 21: 19–22PubMedCrossRefGoogle Scholar
  29. 29.
    Nicholson RI, Maynard PV (1979) Anti-tumour activity of ICI118630, a new potent luteinizing hormone-releasing hormone agonist. Br J Cancer 39: 268–273PubMedCrossRefGoogle Scholar
  30. 30.
    Plowman PN, Nicholson RI, Walker KJ (1986) Remissions of metastatic breast cancer in post-menopausal women with luteinising hormone releasing hormone (ICI 118630) therapy. Eur J Cancer (abstract 111–18 ) 22: 746Google Scholar
  31. 31.
    Pritchard KI, Thomson DB, Myers RE, Sutherland DJA, Mobb BG, Meakin JW (1980) Tamoxifen therapy in premenopausal patients with metastatic breast cancer. Cancer Treat Rep 64: 787–796PubMedGoogle Scholar
  32. 32.
    Santen RJ, Santner S, Davis B (1978) Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 47: 1257–1265PubMedCrossRefGoogle Scholar
  33. 33.
    Santen RJ, Worgul TJ, Samojlike E, Interrante A, Boucher AE, Lipton A, Harvey HA, White DS, Smart E, Cox C, Wells SA (1981) A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer. N Engl J Med 305: 545–551PubMedCrossRefGoogle Scholar
  34. 34.
    Schally AV, Redding TW, Comaru-Schally AM (1984) Potential use of analogs of luteinizing hormone-releasing hormones in the treatment of hormone-sensitive neoplasms. Cancer Treat Rep 68: 281–289PubMedGoogle Scholar
  35. 35.
    Schinzinger AS (1889) Uber Carcinoma mammae. Zentralbl Chir [Suppl] 16: 55–56Google Scholar
  36. 36.
    Stuart-Harris RC, Smith IE (1984) Aminoglutethimide in the treatment of advanced breast cancer. Cancer Treat Rev 11: 189–204PubMedCrossRefGoogle Scholar
  37. 37.
    Stuart-Harris RC, Dowsett M, Bozek T, McKinna JA, Gazet JC, Jeffcoate SL, Kurkure A, Carr L, Smith IE (1984) Low-dose aminoglutethimide in treatment of advanced breast cancer. Lancet 2: 604–607PubMedCrossRefGoogle Scholar
  38. 38.
    Waxman JH, Harland SJ, Coombes RC, Wrigley PFM, Malpas JS, Powles T, Lister TA (1985) The treatment of postmenopausal women with advanced breast cancer with Buserelin. Cancer Chemother Pharmacol 15: 171–173PubMedCrossRefGoogle Scholar
  39. 39.
    Williams MR, Walker KJ, Turkes A, Blarney RW, Nicholson RI (1986) The use of an LH-RH agonist (ICI 118630, Zoladex) in advanced premenopausal breast cancer. Br J Cancer 53: 629–636Google Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1989

Authors and Affiliations

  • K. Höffken
    • 1
  1. 1.University Clinic of Internal Medicine (Tumor Research)West German Tumor CenterEssen 1Germany

Personalised recommendations